BiotechTube
Stimunity

Stimunity

Paris, France· Est.
stimunity.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Stimunity is a Paris-based, privately held biotech founded in 2016, focused on activating the innate immune system via the STING pathway. Its lead platform utilizes engineered virus-like particles (VLPs) designed to deliver STING agonists directly into target cells, aiming to overcome limitations of first-generation STING therapies. The company is in the preclinical stage, backed by €2M in seed funding from Portage Biotech and Horizon 2020 grants, and is led by a team with strong scientific and drug development expertise in immunology and oncology.

OncologyInfectious Diseases

Technology Platform

Engineered Virus-Like Particles (VLPs) designed to deliver STING agonists into target cells to activate the cGAS-STING innate immune pathway.

Opportunities

The significant unmet need in oncology for patients resistant to checkpoint inhibitors creates a large addressable market.
The modular VLP platform could be expanded beyond STING agonists to deliver other immunomodulatory payloads, enabling a pipeline-in-a-product approach.
Strong academic roots and grant funding provide validation and reduce early-stage dilution.

Risk Factors

High technical risk associated with translating a novel VLP-based biologic from preclinical research into a safe and effective human therapeutic.
Intense competition in the STING agonist space from well-funded biotech and large pharma companies with alternative modalities.
Dependence on future financing rounds (Series A+) to advance into clinical trials, subject to market conditions.

Competitive Landscape

The STING agonist competitive landscape includes companies developing intratumoral small molecules (e.g., former Aduro Biotech partners), systemic administration approaches, and other delivery technologies. Stimunity's key differentiator is its VLP delivery system, which aims to improve cellular targeting and uptake compared to first-generation compounds. It must compete on efficacy, safety, and manufacturability.

More companies in Immunotherapy / Immuno-Oncology →More companies in France →